AdvanCell, a clinical-stage radiopharmaceutical company developing cancer therapeutics, has raised $12 million in an oversubscribed Series C financing round.

The funding round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others. This investment will support AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of delivering cancer treatments globally.